Purple Biotech reports biomarker data from CM24 Phase 1 dose escalation study

Purple Biotech provided new results from exploratory analyses conducted as part of a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab. The study enrolled 14 patients with advanced cancers including 11 patients with pancreatic adenocarcinoma, two patients with colorectal adenocarcinoma (CRC) and one patient with papillary thyroid cancer. The analyses conducted in eight evaluable PDAC patients demonstrate clinically meaningful and durable reductions in serum myeloperoxidase, a biomarker for NETs, following treatment with CM24 plus nivolumab, immediately and 15 days after the first administration. In addition, analyses of tumor samples derived from the evaluable PDAC patients suggest that patient survival may be positively associated with higher levels of CEACAM1+ tumor-infiltrating lymphocytes in the TME. These results, along with additional data from this clinical study, are part of the Company’s effort aimed at identifying and evaluating the potential utility of a biomarker to optimize patient selection and treatment. "These encouraging biomarker results provide initial evidence of certain mechanistically relevant biomarkers and may enable us to implement a biomarker-driven strategy that could identify patients who will benefit from CM24," said Gil Efron, Chief Executive Officer, Purple Biotech. "We look forward to further data that may establish these findings in our ongoing randomized Phase 2 clinical study evaluating CM24 in combination with nivolumab and chemotherapy for treatment of PDAC."